Abstract：
OBJECTIVE: The association between hepcidin and acute leukemia (AL) or hematopoietic cell transplantation (HCT) in children and adults remains obscure. We aimed to assess this potential relationship through a systematic review of observational studies.
METHODS: An electronic search of three databases, including PubMed, Scopus, and Web of Science Core Collection, was performed up to 31 March 2022. Two independent reviewers assessed the search results according to predetermined inclusion and exclusion criteria, following PRISMA guidelines.
RESULTS: Of the 3607 titles identified, 13 studies published between 2008 and 2021 met the inclusion criteria. Most studies included a moderate number of participants and controls and used enzyme-linked immunosorbent assay (ELISA) to determine serum hepcidin levels. The principal findings: (1) serum hepcidin levels in patients with AL or undergoing HCT are increased compared to controls, regardless of the patient\'s age and the phase of disease treatment; (2) AL therapy and HCT significantly influence serum hepcidin levels; (3) serum hepcidin may predict a worse outcome in patients with AL and post-HCT.
CONCLUSIONS: This systematic review provides an overview of observational studies that deal with the association of hepcidin with AL and HCT. Although disturbances in iron metabolism are common in AL and HCT, and hepcidin seems to play a cardinal role in their modulation, more extensive research is needed.
METHODS: An electronic search of three databases, including PubMed, Scopus, and Web of Science Core Collection, was performed up to 31 March 2022. Two independent reviewers assessed the search results according to predetermined inclusion and exclusion criteria, following PRISMA guidelines.
RESULTS: Of the 3607 titles identified, 13 studies published between 2008 and 2021 met the inclusion criteria. Most studies included a moderate number of participants and controls and used enzyme-linked immunosorbent assay (ELISA) to determine serum hepcidin levels. The principal findings: (1) serum hepcidin levels in patients with AL or undergoing HCT are increased compared to controls, regardless of the patient\'s age and the phase of disease treatment; (2) AL therapy and HCT significantly influence serum hepcidin levels; (3) serum hepcidin may predict a worse outcome in patients with AL and post-HCT.
CONCLUSIONS: This systematic review provides an overview of observational studies that deal with the association of hepcidin with AL and HCT. Although disturbances in iron metabolism are common in AL and HCT, and hepcidin seems to play a cardinal role in their modulation, more extensive research is needed.
摘要：
目的：儿童和成人中铁调素与急性白血病（AL）或造血细胞移植（HCT）之间的关系仍然不清楚。我们旨在通过对观察性研究的系统评价来评估这种潜在的关系。
方法：对三个数据库进行电子搜索，包括PubMed,Scopus,和WebofScience核心合集,截至2022年3月31日。两名独立审稿人根据预定的纳入和排除标准评估搜索结果，遵循PRISMA准则。
结果：在确定的3607个标题中，2008年至2021年发表的13项研究符合纳入标准。大多数研究包括中等数量的参与者和对照组，并使用酶联免疫吸附测定（ELISA）来确定血清铁调素水平。主要发现：（1）与对照组相比，AL或接受HCT的患者的血清铁调素水平升高，无论患者的年龄和疾病治疗的阶段;（2）AL治疗和HCT显着影响血清铁调素水平;（3）血清铁调素可能预测AL和HCT后患者的预后较差。
结论：本系统综述提供了关于hepcidin与AL和HCT相关性的观察性研究的概述。尽管铁代谢紊乱在AL和HCT中很常见，铁调素似乎在它们的调节中起着重要的作用，需要更广泛的研究。
方法：对三个数据库进行电子搜索，包括PubMed,Scopus,和WebofScience核心合集,截至2022年3月31日。两名独立审稿人根据预定的纳入和排除标准评估搜索结果，遵循PRISMA准则。
结果：在确定的3607个标题中，2008年至2021年发表的13项研究符合纳入标准。大多数研究包括中等数量的参与者和对照组，并使用酶联免疫吸附测定（ELISA）来确定血清铁调素水平。主要发现：（1）与对照组相比，AL或接受HCT的患者的血清铁调素水平升高，无论患者的年龄和疾病治疗的阶段;（2）AL治疗和HCT显着影响血清铁调素水平;（3）血清铁调素可能预测AL和HCT后患者的预后较差。
结论：本系统综述提供了关于hepcidin与AL和HCT相关性的观察性研究的概述。尽管铁代谢紊乱在AL和HCT中很常见，铁调素似乎在它们的调节中起着重要的作用，需要更广泛的研究。
